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Abstract
Historically, Haemophilus inﬂuenzae (Hi) serotype b (Hib) caused most invasive Haemophilus infections worldwide, mainly in children. In
1989 routine childhood vaccination against Hib was initiated in Iceland. We conducted a population-based study of all patients in the
country with Haemophilus spp. isolated from sterile sites (n = 202), from 1983 to 2008. Epidemiology, clinical characteristics of the
infections and serotypes of the isolates were compared during the pre-vaccination (1983–1989) and post-vaccination era (1990–2008).
Following the vaccination, the overall incidence of Hib decreased from 6.4 to 0.3/100 000 per year (p <0.05) whereas the incidence did
not change signiﬁcantly for infections caused by Haemophilus sensu lato not serotype b, hereafter referred to as non-type b Hi (0.9 vs
1.2, respectively). The most frequent diagnosis prior to 1990 was meningitis caused by Hib, which was subsequently replaced by pneu-
monia and bacteraemia caused by non-type b Hi. Most commonly, non-type b Hi were non-typeable (NTHi; 40/59), followed by Hi
serotype f (14/59) and Hi serotype a (3/59). Pregnancy was associated with a markedly increased susceptibility to invasive Haemophilus
infections (RR 25.7; 95% CI 8.0–95.9, p <0.0001) compared with non-pregnant women. The case fatality rate for Hib was 2.4% but 14%
for non-type b Hi, highest at the extremes of age. Hib vaccination gives young children excellent protection and decreases incidence in
the elderly due to herd effect in the community. Replacement with other species or serotypes has not been noted. Pregnant women
are an overlooked risk group.
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Introduction
Haemophilus inﬂuenzae (Hi) are classiﬁed according to their
capsular polysaccharides into six serotypes (a–f) and
non-capsular strains [1]. Encapsulated strains, especially Hi
type b (Hib), are aggressive pathogens that primarily cause
infections in children <5 years of age because of their lack of
T-cell independent response to polysaccharides [2]. This
capsular type caused more than 95% of invasive H. inﬂuenzae
infections in Scandinavian children before routine vaccination
was initiated against Hib [3]. On the other hand, Hi carrying
other capsular types and non-capsular strains (Haemophilus
sensu lato not serotype b, hereafter referred to as non-type
b Hi) commonly cause invasive infections in persons with
comorbidities [4,5]. In May 1989, routine vaccination against
Hib was started in Iceland with the vaccine PRP-D (Pro-
HIBiT), followed by a dramatic decrease in Hib disease [6].
Despite the early success of vaccination against Hib, the
concern remains that during longer follow-up, non-type b Hi
with other capsular types or non-typeable Hi (NTHi) strains
may replace Hib. Recent studies have been inconclusive
regarding this matter [5,7,8]. Furthermore, with reduced
pharyngeal carriage a natural booster to antibody production
may be lost, resulting in waning immunity [9]. The purpose
of this study was to analyse trends in invasive disease caused
by H. inﬂuenzae in Iceland for 26 years, from 1983 to 2008,
at the 20-year anniversary of nationwide childhood vaccina-
tion against Hib in Iceland.
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Materials and Methods
Setting and clinical data
In May 1989, routine vaccination against Hib was started in
Iceland with the vaccine PRP-D (ProHIBiT). The vaccine was
administered at the age of 3, 4, 6 and 14 months, and during
the ﬁrst year of immunisation children at the age of 1–3 years
were offered one dose [6]. From 2000 to 2005 Pentavac
was used, followed by Infanrix-Polio+Hib at the age of 3, 5
and 12 months (http://www.landlaeknir.is). This nationwide
long-term comparative study of invasive infections caused by
Haemophilus spp., included 6 years in the pre-vaccine era
(1983–1989) and 20 years following implementation of Hib
vaccination in 1989 (1990–2008). All patients with Haemophi-
lus spp. isolated from cerebrospinal ﬂuid (CSF), blood or joint
ﬂuid from 1 January 1983 to 31 December 2008 were identi-
ﬁed retrospectively by a nationwide search in microbiology
databases. For the sake of completeness, all serogroups of
H. inﬂuenzae were included, in addition to NTHi as well as
infections caused by H. parainﬂuenzae. Information regarding
age, sex, date of diagnosis, source of isolate (blood, CSF or
joint ﬂuid) and vital status 30 days from diagnosis was avail-
able for all patients. Permission to access more detailed clini-
cal information concerning the 202 cases was received from
all hospitals and health clinics in Iceland. Of these, 191 charts
were retrieved, thus giving a yield of 95%. Clinical information
was reviewed and registered, including clinical presentation,
signs and symptoms, past medical history, laboratory results,
antibiotic therapy and outcomes. The National Bioethics
Committee of Iceland and the Data Protection Authority of
Iceland approved the study.
Microbiology
Information was collected regarding blood culture results
and cultures of CSF, serotypes of the isolates and beta-lac-
tamase production. Isolates were serotyped using Difco Hae-
mophilus inﬂuenza antiserum (Becton Dickinson, Sparks, MD,
USA). Beta-lactamase production was tested for with the
clover leaf test until the year 2000 and thereafter with the
Nitrocephin test (Oxoid, Cambridge, UK).
Statistics
For calculations of age-speciﬁc incidence, population data
were obtained from Statistics Iceland (http://www.statice.is).
Data from this source were also used to calculate the aver-
age total fertility rate of Icelandic women, as well as mean
live births and late foetal deaths per year in 1983–2008. The
total fertility rate was used to calculate the annual number
of pregnancy-years, assuming 9 months of gestation for the
cohort. Data on induced abortions in Iceland during 1982–
2009 and their timing during gestation were obtained from
the Directorate of Health (http://www.landlaeknir.is/
Heilbrigdistolfraedi/Fostureydingar) and used to calculate the
number of additional pregnancy-years that were not associ-
ated with live births or late foetal deaths. The number of
unregistered, spontaneous abortions was assumed to be 16%
of live births and follow the same timeline [10]. These num-
bers were combined to calculate the average annual number
of pregnancy-years of the nationwide cohort. Incidence of
invasive Haemophilus disease in pregnant women was then
calculated as the ratio between the number of annual preg-
nancy-associated infections and pregnancy-years and
expressed as the number of infections for every 100 000
pregnancy-years. The incidence rates in pregnant and non-
pregnant women of childbearing age were compared using
‘Comparing time person-time rates’, which gave rate ratios
and 95% conﬁdence intervals (95% CI). Statistical analysis
was performed by using OpenEpi (http://www.openepi.com).
Proportions were compared by using v2 and Fisher exact
tests. A p value of <0.05 was considered signiﬁcant. All
comparisons were two-tailed.
Results
During the 26 years of study, 202 cases of invasive Haemo-
philus infections were diagnosed in Iceland. During 1983–
1989, before routine childhood vaccination against Hib, 123
infections were identiﬁed, 104 (85%) of them in children
<16 years of age. In the post-vaccination era 1990–2008, 79
cases were diagnosed, 25 (32%) of them children. The annual
numbers of Hib and non-type b Hi infections in Iceland,
1983–2008, are shown in Fig. 1. Age-speciﬁc incidence rates
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FIG. 1 Yearly number of invasive Hib and non-type b Hi infections
in Iceland.
CMI Berndsen et al. Haemophilus in the post-vaccination era 919
ª2011 The Authors
Clinical Microbiology and Infection ª2011 European Society of Clinical Microbiology and Infectious Diseases, CMI, 18, 918–923
for invasive Hib and non-type b Hi disease, before and after
Hib vaccination, are presented in Table 1. The yearly inci-
dence of Hib dropped by 96% (95% CI, 92.8–97.6), from 6.4/
100 000/year before 1990, to 0.3/100 000/year following
adoption of routine childhood immunisation (p <0.0001).
The incidence of non-type b Hi during 1983–1989 had a
yearly incidence of 0.9/100 000/year and increased to 1.2/
100 000/year post-Hib vaccination, but this was not a signiﬁ-
cant increase (p 0.16). The reduction in incidence of invasive
Hib infections was most pronounced among children aged
<1 and 1–5 years (p <0.05).
About one in ﬁve of all Hib isolates tested for beta-
lactamase production were positive (24 of 115 isolates
tested, 21%), whereas 16% of non-type b Hi isolates tested
were positive. The association between clinical diagnosis and
species or serotypes, as well as timing of the infection, is
summarised in Table 2. As shown, NTHi were most com-
monly isolated from patients with pneumonia or bacteraemia
in the post-vaccine era, followed by H. inﬂuenzae type f (Hif),
which primarily caused bacteraemic pneumonia. Only seven
cases (3.5%) of all invasive disease were caused by H. parain-
ﬂuenzae and the epidemiology of this species remained sta-
ble. Meningitis was the most frequent diagnosis (63/202,
31%) in the cohort, most commonly caused by Hib in chil-
dren in the pre-vaccination period. Almost one-quarter (13/
57, 23%) of the children with meningitis suffered from long-
term sequelae, most commonly hearing loss. In the post-vac-
cination era bacteraemic pneumonia caused by non-type b Hi
became the most frequent clinical presentation of invasive
disease.
Predisposing conditions of children and adults with Hib
and non-type b Hi are summarized in Table 3. As shown,
severe underlying disease was more frequent among both
children and adults with non-type b Hi infections compared
with those with Hib. Antecedent viral infection diagnosed
clinically was commonly reported in children with Hib,
whereas children with non-type b Hi were more likely to
suffer from chronic conditions.
Among 18–40-year-old women, 13 were diagnosed with
Haemophilus disease, nine of whom were pregnant, and ﬁve
of them lost their foetus (median gestational age 12 weeks
compared with 40 weeks for those who gave birth). Accord-
ing to nationwide data on fertility, late foetal deaths and
induced abortions, combined with previously published data
on frequency of spontaneous abortions [10], the incidence of
invasive Haemophilus disease in pregnant women was 9.2
infections/100 000/year (nine infections during 98 014 per-
son-years), whereas non-pregnant women in the same age
group had an incidence of 0.4/100 000/year (four infections
during 1 118 167 person-years). The rate ratio between the
two groups is 25.7 (95% CI, 8.0–95.9; p <0.0001). Non-type
b Hi caused 6/9 of the infections in pregnancy and 8/11 of
the neonatal infections, where the majority was caused by
NTHi (5/6 and 4/8, respectively). The infection was fatal in
two neonates (NTHi and non-type b Hi) while all the
pregnant women survived.
Of the 14 fatal cases, three were caused by Hib; one
severely disabled child had not received vaccination, in the
post-vaccine era, and two adults in the pre-vaccine era
TABLE 1. Age-speciﬁc incidence for infections caused by
Haemophilus inﬂuenzae type b (Hib) and other (non b Hi)
Age
1983–1989 1990–2008
Hib Non-b Hi Hib Non-b Hi
n Incidence n Incidence n Incidence n Incidence
<1 32 109.0 2 6.8 3 3.8 7 8.9
1–5 6 41.1 1 0.7 3 0.7 9 2.2
6–20 5 1.1 2 0.5 0 0 4 0.2
21–40 1 0.2 1 0.2 5 0.3 13 0.8
41–60 4 1.3 2 0.6 1 0.1 8 0.7
>60 5 2.2 6 2.7 2 0.3 23 2.7
All incidence values represent number of cases/100 000 population/year.
TABLE 2. Clinical diagnosis according to species, serotype and time interval
Diagnosis
Serotype/species 1983–1989 1990–2008
a b c d e f NTHi Parainﬂuenzae Non b Uncertain Hib Non-Hib Hib Non-Hib
Pneumonia 1 12 1 6 16 4 9 4 3 24
Meningitis 58 3 1 55 2 3 2
Bacteremia 2 16 1 2 16 3 14 5 2 19
Epiglottitis 4 1 4 1
Cellulitis 10 2 1 1 1 10 1 4
OM/SA 10 1 1 9 1 2
Other 5 1 6 2 3 1 2 4 10
NA 8 1 2 7 1 3
All cases 3 123 2 1 1 14 40 7 3 8 109 14 14 65
NR, diagnosis not available.
For diagnosis according to serotype all cases were included. OM/SA, osteomyelitis/septic arthritis.
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died from septicaemia and pneumonia. Thus, the case fatal-
ity rate for Hib was 2.4%. The case fatality rate for non-
type b Hi was 14%. The highest fatality rates were
observed at the extremes of age, <1 year (2/10, 20%), 41–
60 years (2/9, 22%) and >60 years (7/33, 21%). Of the 11
non-type b Hi strains associated with fatal infections, two
were encapsulated, serogroups c and f, six were NTHi
and three were only classiﬁed as non-type b Hi. The most
common causes of death were pneumonia (7/11) and bac-
taeremia (3/11).
Discussion
This study conﬁrms a remarkable and sustained success of
Hib conjugate vaccination in Iceland. During the two dec-
ades of follow-up where all species of invasive Haemophilus
spp. were included, an increase in Hib infections was not
noted. This contrasts with the early experience from the
United Kingdom [11,12]. In Iceland a booster dose was used
from the beginning, which may explain this difference [6].
During the last 5 years of our study, Hib was all but elimi-
nated, occurring in only one of 24 (4%) invasive infections.
Similar to the results of others, the reduction in incidence
of Hib was most pronounced among young children, and
from 1990 onwards non-type b Hi infections became more
than twice as common as Hib in young children [9,12].
Interestingly, the incidence of invasive Hib infections also
decreased markedly in the elderly after childhood vaccina-
tion was initiated. This reduction is most likely caused by
the herd effect, where the unvaccinated elderly beneﬁt from
the reduction in nasopharyngeal carriage of Hib in vacci-
nated children, leading to reduced exposure and subsequent
infections [13,14]. Most studies have concentrated on the
age-group 0–4 years although Perdue et al. and Peltola et al.
[3,15] also demonstrated a reduction in incidence of invasive
disease among adults in Alaska and Scandinavia.
The age group 21–40 is of particular interest, childbearing
women in particular. It has been proposed that the immuno-
suppressive effects of pregnancy increase the susceptibility of
the host to H. inﬂuenzae infections [16]. We found a signiﬁ-
cant increase in incidence among pregnant women compared
with other women of the same age. A prospective study
found that child-bearing women in the age group 18–
39 years had a six-fold increased risk of H. inﬂuenzae bacter-
aemia compared with adults of the same age [17]. Our
results show that the relative risk associated with pregnancy
may be even higher. Carriage studies have shown that only
1.8/1000 parturient women carry non-encapsulated Hi in
their genital tract [18], but they were found in 8/110 women
with preterm rupture of membranes [19]. It has been sug-
gested that unusually virulent NTHi biotype II or IV strains
may preferentially cause invasive infections among neonates
and pregnant women [19–21]. Further characterization of
the strains in our study may therefore be of interest. The
incidence of non-type b Hi infections among infants younger
than 1 year from 1990 to 2008 was 8.9/100 000/year, which
is similar to the results of Ladhani et al. [9].
Currently, NTHi are the most common types of Hi caus-
ing invasive disease in Iceland, similar to results of large-scale
studies from Australia, Canada and Denmark [22]. Hif are
currently the most common encapsulated invasive H. inﬂuen-
zae isolates in Iceland. Hif infections are similar to NTHi in
that 10/14 (72%) cases had severe predisposing conditions
and the most common clinical diagnosis was pneumonia.
Other studies have reported a high prevalence (60–80%) of
predisposing conditions among patients with Hif infections
[12,23] and they are most frequent in young individuals and
the elderly [4,23]. Resman et al. [24] recently reported a sig-
niﬁcant increase in serious invasive infections ascribed to Hif,
mainly in individuals >60 years of age in Sweden. This reso-
nates well with our study, as 9/14 (64%) Hif patients were
>60 years of age. A recent study from Utah shows the
emergence of H. inﬂuenzae type a as the most common in
TABLE 3. Predisposing conditions in children and adults with Hib infections compared with non b Hi (n = 191)
Predisposing condition
Children Adults
Hib, n = 101 (%) Non b Hi, n = 24 (%) OR (95% CI) p value Hib, n = 14 (%) Non b Hi, n = 52 (%) OR (95% CI) p value
Smoking 6 (43) 19 (37) 1.3 (0.4–4.4) 0.7
Alcoholism 1 (7) 4 (8) 1.1 (0.1–29) 0.9
Viral symptoms 43 (43) 6 (25) 2.2 (0.8–6.5) 0.12 4 (8)
Pregnancy 3 (21) 6 (12) 2.1 (0.4–9.7) 0.4
Otitis media 36 (36) 2 (8) 6.0 (1.5–39.9) 0.01 1 (7) 1 (2) 3.8 (0.1–155) 0.4
CV disease 2 (2) 2 (8) 4.4 (0.4–44.4) 0.2 2 (14) 22 (42) 4.3 (1.0–31) 0.06
Lung disease 3 (3) 3 (13) 4.5 (0.7–28.4) 0.09 3 (21) 12 (23) 1.1 (0.3–5.6) 0.9
Cancer 1 (1) 2 (13) 8.9 (0.6–270) 0.1 2 (14) 14 (27) 2.2 (0.5–15) 0.4
OR, odds ratio; CV disease, cardiovascular disease.
If patients had more than one predisposing condition they were all included.
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children, leading to a disease similar to Hib [25]. A similar
increase was not noted in our study.
Viral infections of the upper airway make patients more
prone to colonization and infection with both Hib and non-
type b Hi [26,27]. Interestingly, a higher proportion of
patients with Hib reported a history of preceding viral infec-
tion, which may be explained in part by the different age
composition of the two groups. However, a similar differ-
ence was also noted with respect to otitis media, which was
the second most frequent predisposing condition among chil-
dren with Hib infections, 36/101 (36%), while children with
NTHi infections had a history of otitis media in only 2/24
(8%) cases (p 0.01). This is somewhat surprising, because
NTHi frequently cause otitis media in children [7], but this
may be indirect evidence of the relative lack of invasive
potential of these strains. Similarly, children who were
infected with non-type b Hi were more likely to have severe
predisposing conditions. This is in agreement with other
studies and reinforces that non-type b Hi are opportunistic
pathogens with less virulence compared with Hib [4,7,12].
The most common predisposing condition among adults with
Hib infections was smoking, which has been linked to
increased susceptibility to infections [28]. As other authors
have concluded, adults with non-type b Hi infections fre-
quently had serious predisposing conditions, most commonly
coronary artery disease, lung disease and malignant disease
[8,12,29].
The age-related fatality rate for patients with Hib was
2.4% and for non-type b Hi infections it was 14%, being high-
est at the extremes of age, which is in accordance with data
from Scandinavia, the United Kingdom and the USA
[5,11,30]. With the availability of a conjugated vaccine for
NTHi, it may therefore be prudent to study the effectiveness
of this vaccine in select groups of adult patients with predis-
posing conditions, including young women. The strength of
our study is its population-based design, giving a clear picture
of the epidemiology of invasive Haemophilus disease before
and after vaccination for Hib. Despite the long time-frame,
clinical information was still available for 95% of the cases.
The main limitation of our study is the limited power in sta-
tistical analyses of small subgroups.
In conclusion, we present a population-based study of
invasive Haemophilus disease in Iceland, spanning 26 years.
Following vaccination, which started in 1989, invasive infec-
tions caused by Hib were reduced by 96%, in part by the
herd effect. The concern that other non-type b Hi species
might replace Hib has not materialized after 20 years of fol-
low-up. Pregnancy is an important risk factor, which may be
amenable to prevention, either by selective screening and
antibiotic therapy or by vaccination. The high case fatality
rate of non-type b Hi infections in the elderly with underly-
ing conditions also raises questions regarding the potential
efﬁcacy of vaccination for NTHi in this risk group.
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